H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The firm ...

Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara ...

Transcat (NASDAQ:TRNS – Get Free Report) had its target price cut by stock analysts at HC Wainwright from $126.00 to $106.00 ...

Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy ...

Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Surrozen (NasdaqCM:SRZN) with a Buy ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target ...